Effect of IFN-γ on Innate Immune Cells

Completed · Phase 1

Conditions studied: Chronic Granulomatous Disease

In brief

The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-γ-1b, Actimmune\*) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The investigators will evaluate the effects of IFN-γ in healthy human subjects in vivo on gene expression, biologic activity markers, and functional activity of myeloid cells in single dose studies and in steady state studies.

Key facts

Study ID

NCT02609932

Run by

University of Colorado, Denver

People needed

20

Starts

2016-07-01

Expected to finish

2019-02-01

Last updated by the study team

2019-02-15

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adults over the age of 18 years up to 60 years.
• At time of screening subject is well and healthy;
• Acute infections resolved;
• Subject off treatment medications;
• No diagnosis of chronic conditions or active health care issues for which the subject is actively followed by a health care provider or is on chronic medications.
• Non-prescription medications for mild inter-current illnesses will be allowed at the discretion of the principal investigator.

You may not qualify if…

• Pregnancy.
• History of current infection;
• Two weeks from most recent intercurrent infection;
• History of recurrent infections or immunodeficiency.

Where it is running

• University of Colorado Denver, Anschutz Medical Campus — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.